Yayın:
The Two-Year Outcomes of Phacoemulsification Combined with GATT Versus Standalone GATT in Open-Angle Glaucoma: A Comparative Study

dc.contributor.authorYozgat, Zübeyir
dc.contributor.authorSabaner, Mehmet Cem
dc.date.accessioned2026-01-04T21:46:04Z
dc.date.issued2025-02-24
dc.description.abstractBackground/Objectives: The aim of this paper was to evaluate the two-year outcomes of phacoemulsification combined with gonioscopy-assisted transluminal trabeculotomy (PHACO-GATT) versus standalone GATT in terms of efficacy, safety, and surgical success. Methods: This retrospective, comparative study included 64 eyes of 64 patients with moderate-to-severe open-angle glaucoma: 35 patients (54.7%) with primary open-angle glaucoma (POAG) and 29 patients (45.3%) with pseudoexfoliative glaucoma (PEG). Group 1 (n = 38) underwent PHACO-GATT, and Group 2 (n = 26) underwent standalone GATT. Data, including intraocular pressure (IOP), the number of anti-glaucomatous medications, and complications, were analyzed preoperatively and postoperatively (1st, 3rd, 6th, 12th, and 24th months). Surgical success was defined as achieving a ≥ 20% IOP reduction or IOP ≤ 21 mmHg with or without medications. Results: The mean age was 74.4 ± 7.2 years in Group 1 and 70.8 ± 7.3 years in Group 2. Both groups achieved significant IOP reductions at the 24-month follow-up: Group 1 from 28.6 ± 6.3 mmHg to 12.7 ± 2.4 mmHg, and Group 2 from 27 ± 4.8 mmHg to 13 ± 1.7 mmHg (both p < 0.001). BCVA in Group 1 improved significantly from 0.77 ± 0.29 logMAR to 0.28 ± 0.13 logMAR at 24 months (p < 0.001), while in Group 2, it remained stable at 0.46 ± 0.19 logMAR at baseline and 0.47 ± 0.19 logMAR at 24 months (p > 0.05). The mean number of anti-glaucoma medications decreased significantly in both groups (p < 0.001) without significant intergroup differences (p > 0.05). Complication-free rates were 68.4% in Group 1 and 69.2% in Group 2 (p = 0.899). Surgical success rates were comparable between groups at 12 (100% in both groups) and 24 months (94.7% in Group 1, 96.2% in Group 2). Conclusions: Both PHACO-GATT and standalone GATT demonstrated comparable efficacy and safety over a two-year period. PHACO-GATT provided significant visual acuity improvements due to cataract extraction, making it a suitable option for patients with coexisting cataracts and glaucoma.
dc.description.urihttps://doi.org/10.3390/diagnostics15050542
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/40075790
dc.description.urihttp://dx.doi.org/10.3390/diagnostics15050542
dc.description.urihttps://doaj.org/article/d302db929a4944e890b1c27ba8569dd4
dc.identifier.doi10.3390/diagnostics15050542
dc.identifier.eissn2075-4418
dc.identifier.openairedoi_dedup___::af7e8613c0f8054881c6974ebc07bdef
dc.identifier.orcid0000-0001-5248-5562
dc.identifier.orcid0000-0002-0958-9961
dc.identifier.pubmed40075790
dc.identifier.scopus2-s2.0-86000506477
dc.identifier.startpage542
dc.identifier.urihttps://hdl.handle.net/20.500.12597/42518
dc.identifier.volume15
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.ispartofDiagnostics
dc.rightsOPEN
dc.subjectgonioscopy-assisted transluminal trabeculotomy
dc.subjectMedicine (General)
dc.subjectR5-920
dc.subjectcombined surgery
dc.subjectglaucoma surgery
dc.subjectphacoemulsification
dc.subjectminimally invasive glaucoma surgery
dc.subjectArticle
dc.titleThe Two-Year Outcomes of Phacoemulsification Combined with GATT Versus Standalone GATT in Open-Angle Glaucoma: A Comparative Study
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Zübeyir Yozgat","name":"Zübeyir","surname":"Yozgat","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0001-5248-5562"},"provenance":null}},{"fullName":"Mehmet Cem Sabaner","name":"Mehmet Cem","surname":"Sabaner","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0002-0958-9961"},"provenance":null}}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"gonioscopy-assisted transluminal trabeculotomy"},"provenance":null},{"subject":{"scheme":"keyword","value":"Medicine (General)"},"provenance":null},{"subject":{"scheme":"keyword","value":"R5-920"},"provenance":null},{"subject":{"scheme":"keyword","value":"combined surgery"},"provenance":null},{"subject":{"scheme":"keyword","value":"glaucoma surgery"},"provenance":null},{"subject":{"scheme":"keyword","value":"phacoemulsification"},"provenance":null},{"subject":{"scheme":"keyword","value":"minimally invasive glaucoma surgery"},"provenance":null},{"subject":{"scheme":"keyword","value":"Article"},"provenance":null}],"mainTitle":"The Two-Year Outcomes of Phacoemulsification Combined with GATT Versus Standalone GATT in Open-Angle Glaucoma: A Comparative Study","subTitle":null,"descriptions":["<jats:p>Background/Objectives: The aim of this paper was to evaluate the two-year outcomes of phacoemulsification combined with gonioscopy-assisted transluminal trabeculotomy (PHACO-GATT) versus standalone GATT in terms of efficacy, safety, and surgical success. Methods: This retrospective, comparative study included 64 eyes of 64 patients with moderate-to-severe open-angle glaucoma: 35 patients (54.7%) with primary open-angle glaucoma (POAG) and 29 patients (45.3%) with pseudoexfoliative glaucoma (PEG). Group 1 (n = 38) underwent PHACO-GATT, and Group 2 (n = 26) underwent standalone GATT. Data, including intraocular pressure (IOP), the number of anti-glaucomatous medications, and complications, were analyzed preoperatively and postoperatively (1st, 3rd, 6th, 12th, and 24th months). Surgical success was defined as achieving a ≥ 20% IOP reduction or IOP ≤ 21 mmHg with or without medications. Results: The mean age was 74.4 ± 7.2 years in Group 1 and 70.8 ± 7.3 years in Group 2. Both groups achieved significant IOP reductions at the 24-month follow-up: Group 1 from 28.6 ± 6.3 mmHg to 12.7 ± 2.4 mmHg, and Group 2 from 27 ± 4.8 mmHg to 13 ± 1.7 mmHg (both p &lt; 0.001). BCVA in Group 1 improved significantly from 0.77 ± 0.29 logMAR to 0.28 ± 0.13 logMAR at 24 months (p &lt; 0.001), while in Group 2, it remained stable at 0.46 ± 0.19 logMAR at baseline and 0.47 ± 0.19 logMAR at 24 months (p &gt; 0.05). The mean number of anti-glaucoma medications decreased significantly in both groups (p &lt; 0.001) without significant intergroup differences (p &gt; 0.05). Complication-free rates were 68.4% in Group 1 and 69.2% in Group 2 (p = 0.899). Surgical success rates were comparable between groups at 12 (100% in both groups) and 24 months (94.7% in Group 1, 96.2% in Group 2). Conclusions: Both PHACO-GATT and standalone GATT demonstrated comparable efficacy and safety over a two-year period. PHACO-GATT provided significant visual acuity improvements due to cataract extraction, making it a suitable option for patients with coexisting cataracts and glaucoma.</jats:p>"],"publicationDate":"2025-02-24","publisher":"MDPI AG","embargoEndDate":null,"sources":["Crossref","Diagnostics (Basel)","Diagnostics, Vol 15, Iss 5, p 542 (2025)"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Diagnostics","issnPrinted":null,"issnOnline":"2075-4418","issnLinking":null,"ep":null,"iss":null,"sp":"542","vol":"15","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::af7e8613c0f8054881c6974ebc07bdef","originalIds":["diagnostics15050542","10.3390/diagnostics15050542","50|doiboost____|af7e8613c0f8054881c6974ebc07bdef","od_______267::f1eed919c29a1757f5df685a8d5abd5b","40075790","PMC11898442","50|od_______267::f1eed919c29a1757f5df685a8d5abd5b","oai:pubmedcentral.nih.gov:11898442","oai:doaj.org/article:d302db929a4944e890b1c27ba8569dd4","50|doajarticles::81031163acdacacbda3582d6646bdb7c"],"pids":[{"scheme":"doi","value":"10.3390/diagnostics15050542"},{"scheme":"pmid","value":"40075790"},{"scheme":"pmc","value":"PMC11898442"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":1,"influence":2.5758093e-9,"popularity":3.6405325e-9,"impulse":1,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.3390/diagnostics15050542"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.3390/diagnostics15050542"],"publicationDate":"2025-02-24","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"40075790"},{"scheme":"pmc","value":"PMC11898442"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/diagnostics15050542"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/40075790"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/diagnostics15050542"}],"license":"CC BY","type":"Other literature type","urls":["http://dx.doi.org/10.3390/diagnostics15050542"],"publicationDate":"2025-02-24","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.3390/diagnostics15050542"}],"type":"Article","urls":["https://doaj.org/article/d302db929a4944e890b1c27ba8569dd4"],"publicationDate":"2025-02-01","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar